CMS ranks labs as 'moderate' risk.

MLO Med Lab Obs

Ober/Kaler's Health Law Group, USA.

Published: May 2011

Download full-text PDF

Source

Publication Analysis

Top Keywords

cms ranks
4
ranks labs
4
labs 'moderate'
4
'moderate' risk
4
cms
1
labs
1
'moderate'
1
risk
1

Similar Publications

During 2020-21, states established essential caregiver (EC) programs which allowed nursing home residents to receive in-person supports during the COVID-19 pandemic. This study presents comparative data on the designs of these programs. We conducted on-line searches for federal and states' nursing home visitation and reopening guidelines published in 2020-22.

View Article and Find Full Text PDF

Background The United States continues to rank as one of the most expensive healthcare systems in the world, and cataract surgery, the most commonly performed surgery, is one of the primary drivers of healthcare expenditure. Increasing efforts have been made to try to minimize U.S.

View Article and Find Full Text PDF

Coamorphous drug delivery systems have received increasing interest owing to their potential to improve the solubility, dissolution and bioavailability of poorly water-soluble drugs. However, the crystallization risk is one of major limitations in their application. It has been widely recognized that the coformer plays a vital role in physical stability of coamorphous formulation.

View Article and Find Full Text PDF

Introduction: In 2021, among all age groups, falls ranked as the third leading cause of unintentional injury death in the USA. Unlike fatal data, which rely on death certificates as the gold standard, there is not a gold standard for non-fatal data. Non-fatal falls data are often based on insurance claims or administrative billing data.

View Article and Find Full Text PDF

Background: The Centers for Medicare and Medicaid Services (CMS) recently announced the Maximum Fair Price for the first 10 Medicare Part D drugs selected for price negotiation. By February 2025, CMS should announce the list of Part D drugs to be negotiated with implementation of the negotiated prices in 2027.

Objective: To identify up to 15 Medicare Part D single-source drugs anticipated to be selected by CMS for price negotiation in 2025.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!